Managed care organizations are warning that draft guidelines recently published by the federal agency charged with policing government health programs could impede efforts to control prescription drug costs.
The groups are particularly concerned about language questioning the legality of the rebates and other discounts health plans and pharmacy benefit managers (PBMs) get from drug manufacturers to switch patients from a manufacturer’s drug to a rival product.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!